Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Amyris Partners with J&J Innovation for Biosynthetic Drug Discovery

By Globe Newswire | June 6, 2016

Amyris, Inc. has entered into a research agreement with a commercial license option with Janssen Biotech, Inc., part of Janssen Pharmaceutical Companies. Under the terms of the agreement, facilitated by Johnson & Johnson Innovation, the collaboration will use Amyris’s µPharmTM platform technology to develop a customized library of natural and natural-like compounds to test against Janssen’s therapeutic target.

Nature has been a great source for therapeutics, ranging from antibiotics to statins that lower cholesterol levels; however, Nature’s potential is often under-utilized due to scarcity or unavailability. Amyris’s µPharm platform technology enables an integrated discovery and production process for therapeutic compounds. It not only provides access to scarce natural compounds, but also creates new diversity based on natural compound scaffolds.

“We’re pleased to add another strong partner to our collaboration portfolio and this agreement is consistent with our overall business model of upfront development investment by a partner and an opportunity for a long term revenue stream following successful commercialization,” said Cynthia Bryant, Amyris Senior Vice President Corporate Development & Collaborations. “This technology opens a new area of compounds that have never been accessible for new drug discovery.”

Over the course of the agreement, Amyris will utilize the µPharm platform technology to develop a library of natural and natural-like compounds and test the efficacy of those compounds in vivo for hits against Janssen’s identified target. This is a different approach than traditional high throughput screening, which typically applies thousands of chemical compounds in in vitro screens to find a drug candidate. Instead, the µPharm platform starts with the target, identifies candidate natural compound structures, and then creates diversity around those structures for in vivo testing. The result can lead to increased speed and enhanced efficiency in identifying hits while accelerating the time to market commercialization.

“We are helping to take some of the guess work out of new drug discovery, which helps our partners, like Janssen, to be able to more quickly understand target interaction and ultimately discover new therapies faster,” explained Joel Cherry, Amyris’s President, Research and Development.

“Janssen has a successful history of identifying and tapping into new innovation through collaborations. They are an ideal partner for Amyris to demonstrate the benefits of our µPharm platform technology while improving the health of everyone in the world,” stated Bryant.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE